















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GLU, 10 mM glutamate; JAMI, 10 µM JAMI1001A, !, kglu on and kglu off, respective forward and 
reverse microscopic rate constants for glutamate; k´glu on and k´glu off, respective forward and 
reverse rate constants for glutamate in the presence of JAMI1001A; !, kjami on and kjami off, 
respective forward and reverse microscopic rate constants for JAMI1001A binding; channel 
opening; ", channel closing rate; !, channel opening rate; #, rate of onset of receptor 
desensitization; $, rate of recovery from channel desensitization. (courtesy Morris Benveniste) 
! ! !29!
!
Figure 2.1:  Chemical structures of three positive allosteric modulators of AMPA (a-amino-
3-hydroxy-5-methyl-4-isoxazole-propionic acid) receptors 
 
CTZ, cyclothiazide (2,4-benzothiadiazine-3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-4-dihydro-2h-1); 
CX614 (2H,3H,6aH-pyrrolidino(2,1-3',2')1,3-oxazino(6',5'-5,4)benzo(e)1,4-dioxan-10-one), a proto-
typical benzamide compound; and JAMI1001A (2-(2-(4-(hydroxymethyl)-3-(trifluoromethyl)-1H-
pyrazol-1-yl)acetamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide), a new chemotype tested 
in this paper. Moieties discussed in the Results include: a trifluoromethyl group attached to a pyrazole 
ring (shown in green), a tetrahydrobenzothiophene moiety (shown in blue), and a carboxamide (red) 
which extends from the tetrahydrobenzothiophene. The extended distal structures are connected by a 




Figure 2.2:  Structural comparison between JAMI1001A and CTZ or CX614 
A) A single molecule of JAMI1001A lies at the interface between two AMPA receptor protomers, 
straddling the axis of symmetry. B, Contact map of JAMI1001A showing polar interactions with GluA2 
(dotted black lines). The pendant hydroxyl of the pyrazole crystallizes in two orientations: one (shown as 
stick) interacts with Ser729 and the isoform-specific Ser754, the other (shown as line) with the main 
chain of Pro494. An additional interaction is found between the side chain hydroxyl of Ser497 with the 
carboxamide of JAMI1001A. C, Two molecules of CTZ lie at the dimer interface, either side of the axis 
of symmetry (left panel). There is significant overlap between moieties at the distal ends of JAMI1001A 
and CTZ, particularly in subsite C (green circles, right panels). D, A single molecule of CX614 lies at the 
interface, straddling the axis of symmetry (left panel). There is significant overlap between the planar 
rings of CX614 and the central, alkyl moiety of JAMI1001A, which occupies subsite A (blue ellipses; 
right panels). This figure was generated with pdb files from the RCSB Protein Data Bank using The 
PyMol Molecular Graphics System (version 1.3, Schrödinger, LLC). The following are shown in cartoon 
representation, aligned manually: Chains A and C of the 3H6T.pdb file for cyclothiazide (Hald et al., 
2009), Chains D and F of the 2AL4.pdb file for CX614 (Jin et al., 2005), and Chain A of JAMI1001A 
(4FAT.pdb). A mask was applied to the CX614 subunit of 2AL4 so only one conformation of CX614 




Figure 2.3:  JAMI1001A modulates AMPA receptor deactivation and desensitization 
A) Modulation of a 1 ms pulse of 10 mM glutamate (deactivation, left) and of a 500 ms pulse of 
glutamate (desensitization, right) of the flip isoform of GluA2 by 100 µM CTZ, 100 µM CX614, and   
100 µM JAMI1001 in outside-out patches of transiently transfected HEK293 cells. Control (No Drug) 
responses are shown in light gray; modulated responses in black. B) Identical parameters measured for the 
flop isoform of GluA2. 
"#!
!
Figure 2.4:  JAMI1001A significantly modulates AMPA receptor deactivation 
A) Mean data for a 1 ms pulse of glutamate demonstrates that JAMI1001 significantly modulates the 
kinetics of channel deactivation for both splice isoforms of GluA2. B) Mean data for 500 ms pulses of 
glutamate demonstrate that JAMI1001A significantly modulates the equilibrium desensitization for both 
splice isoforms of GluA2. n values are indicated in parentheses. A paired student’s t-test demonstrates 
significance, such that *p<.05, **p<.01, ***p<.001. (graphs generated by Kathy Partin) 
! ! !33!
(
Figure 2.5:  Kinetic model of mechanism of action of JAMI1001A 
A) A simplified gating scheme was used to test likely mechanism(s) of action of JAMI1001A. The model 
shows gating conformations in the absence (red) and presence (green) of an allosteric modulator. R, 
receptor; Rdes, desensitized receptor; Glu and Glu2, one and two molecules of glutamate, respectively; M, 
modulator; *, open channel. Transitions are indicated by number and rates are given in table 2.1. B) 
Simulated responses to 1 ms or 500 ms of 10 mM glutamate, with no drug (gray) or in the presence of 10 
mM JAMI1001A (black), demonstrate that electrophysiological data can be well-recapitulated by slowing 
the rate of agonist dissociation for deactivation, together with the rate of onset of desensitization or the 
rate of recovery from desensitization, but not by changing a single rate constant. Thus, JAMI1001A 
















































































































































































































































































































































































































































































































































































































Figure 3.1: R628 lies at a transition in receptor symmetry and forms the “latch” in the 
closed-receptor-state 
A) GluA2 crystal structure from Sobolevsky et al. (2009) showing receptor subunits by color (A: green, 
B: yellow, C: blue, D: red). B) GluA2 amino-acid sequence from L620 in M3 (bottom) to I633 in the 
linker region (top). Subunits A and C feature an extended M3 helix, creating a 4-fold to 2-fold symmetry 
transition over a region inclusive of R628 (highlighted by red) and M629 (magenta). C) The symmetry 
transition positions the R628 sidechain nitrile group of subunits B and D within hydrogen bonding 
distance to the backbone of subunits C and A, respectively. D) R628 of subunits B and D (translucent) 
form a latch with R628 from subunits A and C (opaque), which include M629, the most constrictive area 
over the pore (Sobolevsky et al., 2009) (pink spheres). 
! ! !60!
(
Figure 3.2: Electrophysiological recordings of R628E currents show altered receptor 
kinetics compared to wildtype GluA2 
 
A,B) Representative current traces of outside-out patches pulled from HEK293 cells transfected with 
homomeric GluA2 flip (upper traces) or GluA2 flop (lower traces). R628E mutant (black) normalized to 
wildtype (grey) responses to a 10 mM pulse of glutamate (bar above trace) for 1 ms (a, deactivation) or 
500 ms (b, desensitization). Scale bars: 5 ms for deactivation, 100 ms for desensitization. C-F) 
Comparison of mean data between WT (grey) and R628E (black) shows the R628E mutant to have 
significantly slowed onset of deactivation (c) and increased steady-state current (e) for both flip and flop 
isoforms of GluA2. Only the flop isoform of R628E showed significantly slower desensitization (d), 
whereas only the flip isoform had significantly faster recovery. R628E deactivation data shows the 
weighted mean of 2 exponentials. *p<.05, ***p< .001. g,h) Representative paired-pulse recovery sweep 































































































Figure 3.3: The R628E mutant shows impaired trafficking and formation of aggresomes 
Confocal images of HEK 293 cells transiently-transfected with YFP tagged wildtype (WT) flip (left) or 
YFP tagged R628E flip (right) constructs. Top row: images taken 24 hours after cell transfection; bottom 
row: images taken 48 hours post-transfection. Inset in upper right corner of each panel shows 
magnification of the area drawn by dotted white box. Note the increased number of aggresomes (white 
arrows) in HEK cells transfected with the R628E construct, indicative of disrupted channel trafficking. 





Figure 3.4: The R628E mutant does not occlude effects of modulator for the flip isoform of 
GluA2 
 
A)!Representative current traces of outside-out patches pulled from HEK293 cells transfected with 
homomeric GluA2 flip. R628E mutant (black) normalized to wildtype (grey) responses to a 10 mM pulse 
of glutamate (bar above trace) for 1 ms (left, deactivation) or 500 ms (right, desensitization). Currents 
recorded with glutamate only (Glu) or in continuous presence of 100 µM CTZ or 100 µM CX614  Scale 
bars: 10 ms for deactivation, 100 ms for desensitization. B,C) Mean data for tau deactivation (b) and 
steady-state/peak ratio (c) for flip isoform wildtype (WT) and R628E currents as shown above (black, 

















































A) Representative current traces of outside-out patches pulled from HEK293 cells transfected with 
homomeric GluA2 flop. R628E mutant (black) normalized to wildtype (grey) responses to a 10 mM pulse 
of glutamate (bar above trace) for 1 ms (left, deactivation) or 500 ms (right, desensitization). Currents 
recorded with glutamate only (Glu) or in continuous presence of 100 µM CTZ or 100 µM CX614  Scale 
bars: 10 ms for deactivation, 100 ms for desensitization. B,C) Mean data for tau deactivation (b) and 
steady-state/peak ratio (c) for flip isoform wildtype (WT) and R628E currents as shown above (black, 


















































Figure 3.6: The R628E mutant shows altered agonist affinity, with an isoform specific 
effect in presence of modulator 
 
A) Saturation binding curves for [3H]FW binding to wildtype (WT, open circles, grey line) and R628E  
receptors (closed circles, black line). Binding was measured at 1-400 nM radioligand at 0°C. The data are 
shown as averages and s.e.m. from two experiments in which WT and mutant receptors were tested in 
tandem (absence of error bars indicates that the error was smaller than symbol size). The data points were 
fitted with the sum of two hyperbolic functions (Prism 6, Graphpad Software, Inc., La Jolla, CA) or with 
a single hyperbolic function if statistically preferred. KD and Bmax values are described in the text. These 
data show that both flip (left) and flop (right) R628E receptors exhibit a shift towards higher agonist 
affinity and towards having a single high-affinity component. B,C)  The effect of CTZ (cyclothiazide; b) 
and CX614 (c) was measured using a fixed, 5 nM [3H]FW concentration and varying concentrations of 
drug. Binding at each drug concentration was normalized to that without drug and averaged across 
experiments. Mean data was plotted on the y–axis against the modulator concentration on the x-axis, and 
then fitted with a sigmoidal curve (3-point logistic equation with nHill = 1). In the flop isoform (right 
panels), the CTZ induced reduction in [3H]FW binding was greatly attenuated in R628E (-27% compared 
to -60% in WT). Conversely, the CX614 induced increase in [3H]FW binding was significantly enhanced 
in R628E receptors (+62% compared to +30% in WT). In the flip isoform (left panels), these changes in 
the effectiveness of CTZ and CX614 were much smaller. (data courtesy Markus Kessler) 
3[H] FW

























































































































Figure 3.7: R628E physiological data can be replicated by a mathematical model 
 
A) Model schematic showing receptor states in black. Glutamate binds (R-Glu) to a receptor at rest (R) in 
duplicate (R-Glu2) to cause channel opening (R*-Glu2). Alternatively, receptors can enter desensitized 
states (Rd-Glu, Rd-Glu2). Identical states are seen for receptor in presence of modulator (light grey), with 
modulator binding transitions (grey). B,C) Simulations of flip (upper) and flop (lower) deactivation (c) 
and desensitization (d) using wildtype (WT, grey) and R628E (black) transition parameters. (black bar= 
10 mM glutamate; scale bars = 5ms deactivation, 100ms desensitization). D) Simulated paired-pulse 
recovery of R628Eo using an initial 200ms desensitizing pulse of 10mM glutamate. (scale bar = 100ms). 
E) Plot of data generated in (d). A single exponential was fit to the resulting values (see methods) with a 






















Figure 3.8: Experimental binding data is best modeled by changing both k-off and delta 
 
The experimental data for wildtype (WT, open markers, grey lines of fit) and R628E (filled markers, 
black lines of fit) receptors is shown for [3H]Flurowilliardiine (FW*) binding. Concentration dependent 
agonist binding (left panel) shows higher apparent affinity with R628E receptors, and is best fit by a 
single exponential reflecting loss of a low affinity binding site seen in WT, which is best fit by two 
exponentials reflecting high and low affinity binding sites as described previously (2008, 2006). 
Modulator dependent changes in agonist binding (right panel) shows a respective decrease and increase of 
agonist binding in presence of CTZ and CX614, with R628E receptors showing an overall increase in 
binding for both modulators. Various manipulations to the model (other panels, filled markers and black 
lines) differentially alter output, from no change at all for changing alpha alone to closely recapitulating 
R628E by changing k-off and delta together. An energy state diagram is also shown (far right panels), 
displaying the predicted effect of each manipulation on receptor state stability as predicted by Gibb’s free 
energy (ΔG). Troughs from left to right of upper trace represent: the unbound receptor, the receptor with 
LBD closed on agonist, and the receptor with open channel. The lower trace represents the transition 
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Homomeric WT and R628E GluA2 flip and flop isoform receptor currents were recorded from 
outside-out patches of transiently transfected HEK293 cells. Deactivation and desensitization 
were respectively simulated by 1 ms and 500 ms applications of 10 mM glutamate. Currents 
from R628E receptors were best fit by two exponentials (τFast, τSlow) which were weighted 
(Weighted τ) by percent amplitude (% Fast). The mutant receptors also showed greater steady-
state/peak ratios (SS/peak). Peak amplitudes did not differ significantly for either condition. (see 













Tau 0.81 ± 0.09 ms τDes 8.78 ± 0.62 ms
Steady-state 13.26 ± 3.38 pA
Peak 151.03 ± 30.44 pA
Peak Amplitude 111.85 ± 19.86 pA SS/peak 0.13 ± 0.05
Tau 0.79 ± 0.07 ms τDes 1.64 ± 0.09 ms
Steady-state 7.91 ± 2.28 pA
Peak 99.86 ± 32.71 pA
Peak Amplitude 93.57 ± 41.14 pA SS/peak 0.07 ± 0.02
τFast 1.31 ± 0.25 ms τDes 12.7 ± 2.82 ms
τSlow 12.04 ± 2.04 ms Steady-state 129.50 ± 32.38 pA
% Fast 76.01 ± 4.10% Peak 191.70 ± 55.83 pA
Weighted τ 3.53 ± 0.55 ms SS/peak 0.69 ± 0.03
Peak Amplitude 106.60 ± 13.74 pA
τFast 1.28 ± 0.16 ms τDes 21.10 ± 2.19 ms
τSlow 15.33 ± 3.89 ms Steady-state 114.09 ± 25.41 pA
% Fast 80.30 ± 3.80% Peak 146.80 ± 33.65 pA
Weighted τ 3.29 ± 0.37 ms SS/peak 0.81 ± 0.05
Peak Amplitude 123.21 ± 26.13 pA
R628E_figures! 02/11/2013
! ! !68!
Table 3.2: Transition rates and fold-change from WT for a kinetic model of R628E mutant 
and modulator conditions 
(
(
Rates used for kinetic model (figure 3.7). On and off rates for a WT flop model are shown for the 
no drug (ND) condition. Transitions that use a shared rate are denoted by shade. Transition 7 
represents modulator binding. Transitions 8-13 represent the modulator bound condition (*) of 
transitions 1-6. Table indicates fold-slowing from WT, no drug, condition to replicate 
electrophysiological data in presence and absence of modulator for WT and R628E recordings. 
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Table 3.3: Alterations to agonist binding by a kinetic model of R628E 
 
Model Data Glutamate Binding Binding w/ Modulator 
WT KD High 22.25 ± 1.18 CTZ Min 6.62405 
K
D
 Low 153.08 ± 15.16 EC
50
 20.0619 
% High 61.13 CX614 Max 169.658 
Weighted K
D
 73.10 ± 6.61 EC
50
 14.9654 
Slow Alpha KD High 22.26 ± 1.18 CTZ Min 5.69774 
K
D
 Low 151.73 ± 15.04 EC
50
 20.0625 
% High 61.09 CX614 Top 170.035 
Weighted K
D
 72.64 ± 6.58 EC
50
 14.9652 
Slow K-off KD High 1.19 ± 0.12 CTZ Min 7.41027 
K
D
 Low n/a EC
50
 22.4627 
% High 100 CX614 Min 18.8569 
Weighted K
D
 1.19 ± 0.12 EC
50
 16.6187 




 High 260.31 ± 3.41 CTZ Min 50.1795 
K
D
 Low n/a EC
50
 20.0037 
% High 100 CX614 Max 1050.85 
Weighted K
D
 260.31 ± 3.41 EC
50
 14.9465 
Slow K-off + Delta KD High 13.713 CTZ Min 86.0915 
K
D
 Low n/a EC
50
 20.0244 
% High 100 CX614 Max 179.207 
Weighted K
D





3[H]Flurowilliardiine Binding Binding w/ Modulator 
R628E Flop KD High 24.48 CTZ Min 72.55 
K
D
 Low n/a EC
50
 64.68 
% High 100 CX614 Max 161.5 
Weighted K
D
 24.48 ± 1.13 EC
50
 21.35 
WT Flop KD High 13.74 ± 2.78 CTZ Min 40.21 
K
D
 Low 163.7 ± 33.54 EC
50
 54.83 
% High 23.87 CX614 Max 130.9 
Weighted K
D







Using a step-by-step approach, we extended our model parameters (table 3.2) to investigate how 
specific rate changes affect agonist binding. High and low affinity KD values are presented where 
appropriate. Weighted KD standard error is presented as the weighted error of high and low 
affinity components. Note that model simulations use glutamate as an agonist, where as 
experimental binding assays used [3H]flurowilliardiine. Modulatory conditions resulting in 
decreased binding (<100% normalized) are expressed as the minimum (Min) percentage; with 
























































































































Figure 4.1.1:  Chemical structures of three new potential allosteric modulators (NC 
compounds) in comparison with compounds used in chapter 2 
Similar to JAMI 1001, the NC compounds feature a pyrazole moiety with attached trifluromethyl 
substituent (circled in green, and green on JAMI 1001). The amide substituent of JAMI 1001 (red) is 
varied with NC compounds (circled in red). The NC compounds also show additional closed ring 
structures in place of an extended alkyl chain seen with JAMI 1001. Also note the shortened linker of 
NC1-013 compared to NC2-006 and NC2-022. (Structures for NC compounds courtesy Craig Jamieson, 
other compounds redrawn by John Gieser). 
Figure 4.1.1 Chemical structures of three new potential allosteric modulators (NC 
compounds) in comparison with compounds used in chapter 2 (see figure 2.1).  Similar 
to JAMI 1001, the NC compounds feature a pyrazole moiety with attached trifluromethyl 
substituent (circled in green, and green on JAMI 1001).  The amide substituent of JAMI 
1001 (red) is varied with NC compounds (circled in red).  The NC compou ds also show 
additional closed ring structures in place of an xtended alkyl chain seen with AMI 
1001.  Also not  the shorte ed linker of NC1-013 compared to NC2-006 and NC2-022. 









Figure 4.1.2:  Effects of NC compounds on GluA2 
A) Current responses to 1 ms deactivating glutamate pulses on flip (upper) and flop (lower) GluA2 in 
presence or absence of modulator. Trace color indicates drug condition in co-ordinance with graphs 
below. B) Current responses to 500 ms desensitizing glutamate pulses on flip (upper) and flop (lower) 
GluA2 in presence or absence of modulator. C-E) Graphical representations showing Tau Deactivation 
(c), Tau Desensitization (d) and Steady-state to peak ratio (e). *p<.05, **p<.01, ***p<.001, as assessed 











































































































































































Figure 4.1.2:  Effects of NC compounds on flip and flop GluA2
A) Current responses to 1ms deactivating glutamate pulses on flip (upper) and flop 
(lower) GluA2 in presence or absence of modulator. Trace color indicates drug condition 
in co-ordinance with graphs below. B) Current responses to 500 ms desensitizing 
glutamate pulses on flip (upper) and flop (lower) GluA2 in presence or absence of 
modulator. C-E) Graphical representations showing Tau Deactivation (c), Tau 
Desensitization (d) and Steady-state to peak ratio (E). *p<.05, **p<.01, ***p<.001, as 
assessed using two-way anova with Fisher’s LSD.
! ! !78!




Mean tau deactivation, tau desensitization, and SS/Peak ratio data for NC drug compounds in 
comparison with no drug and JAMI 1001 for flip and flop receptor isoforms. SEM = Standard 




















































































































Table 4.1.1  Mea  NC compound data
Mean deactivation, esensitization, and SS/Peak ratio data for NC drug compounds in comparison

































































































Figure 4.2.1:  Proximity of R628 with pre-M4 flip/flop editing region  
Cartoon (helices shown as cylinders) of GluA2 crystal structure (3KG2.pdb) with overlay 
showing relative b- factor. Inset shows region surrounding R628 residues (shown as spheres in 
CPK colors). Regions in green have more static properties, with magenta colored areas being 
more dynamic. Note the dynamic helices above R628 residues, which include the isoform edited 
KDSG / GGGD (flip / flop) region (residues 776-779). 
Fig 4.2.1: Cartoon of GluA2 crystal structure (3KG2.pdb) overlay showing relative b-
factor with inset showing region surrounding R628 (shown as spheres in CPK colors).  
Regions in green have more static properties, with magenta colored areas being more 
dynamic.  Note the dynamic h lices above R628 re idues, which include the isoform
























































































































































































Fig 4.2.3:  Double mutation of R628 and G779 residues to cysteine shows a synergistic 
effect of individual mutants 
 
Desensitization recordings of outside-out patches pulled from HEK 293 cells expressing GluA2 with 
R628C mutation (top trace), G779C mutation (second tracefrom top) or both mutants together (second 
trace from bottom). The double mutant shows more than an additive effect of either mutant on its own. 
Recordings of deactivation for the double mutant are also shown (bottom trace). 
Fig 4.2.3  Double mutation of R628 and G779 residues to cysteine shows a 
synergistic effect of each individual mutant.  Outside-out patches pulled from HEK 
293 cells expressing GluA2 with R628C mutation (top trace), G779C mutation (second 
tracefro  top) or both mutants together (second trace from botto ).  The double mutant 
shows more than an additive effect f either mut t on its own.  R cordings of 
deactivation for the d uble mutant are lso shown (bottom trace).
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